A written Discord post — no video and no (mm:ss) timestamps, so the "At" cell opens the Discord message. This is a channel-level archive: the reporting voice is Frodsham2866, the speaking voices are Paul Mann (CEO, ASP Isotopes) and Nick Mitchell (COO, Renergen). Note that Mann gave no price or valuation view at all — the 15× / $4.5–5bn discussion was the group's. Research legend: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis.
| Ticker | Name | Research | View | What Mann & Mitchell said | At |
|---|---|---|---|---|---|
| ASPI | ASP Isotopes | QT · SA · STK · FA | Positive | The parent of every thread on this call, and the poster's framing is patient-holder positive. Mann "doesn't discuss" the stock price or valuation — "says it's an investor's job to evaluate that" — and nobody on the call raised it. What he did give: the Renergen helium/LNG plant in commissioning with first shipments early next month; helium contracted at $600/mcf rising toward a potential $1,000 on take-or-pay 5–15 year terms; a $500m DFC + $250m Standard Bank package gated on nameplate Phase 1 production, 50% of Stage 2 contracted and no sales to China, North Korea, Iran or Russia, plus a further $250m raise he expects to be straightforward, with the dilution falling on Noble Africa and ASPI retaining 89%; Si-28 enrichment at 99.5% versus the 99.9995% quantum spec, 80 kg/yr high-purity and half a tonne of 99% capacity; ytterbium into continuous process next month; PET Labs heading for $150m of nuclear-medicine revenue by end of the decade; the QLE spin-out barred before 13 September for US capital-gains reasons, on a ratio already decided but not one-for-one; and a Fermi contract "very close," awaiting a couple more tenants at the Texas plant. Frodsham2866's own read: the pattern of delays and public management-bashing "reminds me forcibly" of GB Group, which he sold after four years and two profit warnings for a £2,500 gain before it went up roughly 30× — a patience lesson offered, he stresses, as an analogy and not a forecast. | read ↗ |
| Renergen | Renergen — ASP Isotopes' helium & LNG business (Virginia project, Free State, South Africa) | — | Positive | The call "was essentially about Renergen," with COO Nick Mitchell alongside Mann. They are commissioning the plant and ramping production, expecting completion and first shipments early next month, and are contracting out production — 3/4 of Stage 1 by the end of next month, half of Stage 2 by the end of the year. "Pricing is very strong": the first helium deal was done at $600/mcf and they are "now seeing prices higher than that, potentially up to $1,000," all take-or-pay 5- to 15-year contracts; LNG is selling between $15 and $20. Renergen's Stage 1 nameplate production and Stage 2 contracting are also two of the three conditions on the $500m DFC / $250m Standard Bank funding. | read ↗ |
| PET Labs | PET Labs Pharmaceuticals — ASP Isotopes' nuclear-medicine unit (South Africa) | — | Positive | "Pet Labs growing very rapidly now and thinks they will get to $150m in nuclear medicine revenue by the end of the decade. That includes YT I think" — the poster's shorthand, most plausibly the ytterbium-derived medical isotope stream, flagged as his own uncertain reading rather than Mann's wording. | read ↗ |
| Noble Africa | Noble Africa — planned Nasdaq-listed helium vehicle (ASPI ~89%) | — | Neutral | The structural answer to the funding gap: after the DFC and Standard Bank conditions are met, a further $250m must be raised, and "Noble Africa will be the only listed helium company on Nasdaq — any dilution should fall on it. ASPI to retain 89% ownership." Frodsham2866 adds his own caveat: "Not sure how that works with the dilution though they do have plenty of cash for that purpose." Not yet trading — no stance on price, only on the mechanism. | read ↗ |
| QLE | Quantum Leap Energy — ASP Isotopes' nuclear-fuels spin-out | — | Neutral | Timing and mechanics, no valuation. The spin-out "will not take place before 13 September as that is the anniversary of the initial IPO" — for US tax and capital-gains reasons — but "could happen quite quickly after this point." Current ASPI shareholders will receive QLE shares, "though not on a one for one basis"; Mann would not be drawn on the ratio, "though it has already been decided." The gating event is commercial: "an actual contractual deal with Fermi is very close. They just need a couple more tenants at the Texas plant… Once that has been released the deal with QLE should be made public." | read ↗ |
Not tabled (people, counterparties and corporate-structure items, not securities carrying a view here): Paul Mann (CEO, ASP Isotopes) and Nick Mitchell (COO, Renergen), the two speakers; Red Chip, which organised the ~10-person call; Frodsham2866 (the member reporting) and Exodus343 (who asked the share-price question). Fermi — the operator of the Texas plant with which "an actual contractual deal is very close," pending a couple more tenants — is named only as a counterparty; no ticker is asserted for it from this post. Skyline Builders (the Hong Kong building company whose sale "seems reasonably imminent") and the two properties and the gold bought this week are described as a trading-company tax requirement, most likely to be sold on; Cove Kaz Capital is the private counterparty to the Kazakh transaction ("a world class asset") that is held up only by finding an auditor for the asset. GB Group is a UK ID-software company from ~22 years ago used purely as the author's personal patience analogy — not a recommendation and not a current position. DFC (the US International Development Finance Corporation) and Standard Bank appear only as lenders.
A jargon-free summary of why each name matters. (These render on the consolidated ticker pages.)
ASP Isotopes is a company that separates isotopes — different weights of the same chemical element — and sells the purified versions. That sounds academic, but each product has a specific customer: silicon-28 is the ultra-pure silicon quantum-computing chips need; ytterbium feeds medical isotope production; and through Renergen the company owns a South African gas field producing helium, which cannot be manufactured and escapes the atmosphere for good once released. It also owns PET Labs, a nuclear-medicine business, and Quantum Leap Energy (QLE), a nuclear-fuel venture it intends to spin out to shareholders. So one listed share is really a bundle of four or five separate businesses at different stages.
The point of this particular post is that a member of the community sat on a small (about ten people) investor call run by Red Chip with the CEO, Paul Mann, and Renergen's COO, and wrote up what was said. The first thing worth knowing is what was not said: Mann "doesn't discuss" the share price or the valuation, on the grounds that valuing the company is the investor's job. So nothing here is management talking the stock up — it is a status report on plants, contracts and paperwork.
The status report is broadly good. The helium plant is being commissioned with first shipments due early September. The gas is being sold under take-or-pay contracts of five to fifteen years — meaning the customer pays for the agreed volume whether or not they take delivery, which turns a commodity into something much closer to a rent. The first deal was struck at $600 per mcf (an "mcf" is a thousand cubic feet of gas) and management says it is now seeing prices "potentially up to $1,000." A $750m debt package ($500m from the US development-finance agency DFC, $250m from Standard Bank) is waiting behind three checkable conditions, plus a further $250m of equity that Mann expects to raise easily. On the enrichment side, silicon-28 has reached 99.5% purity but the quantum-computing specification is 99.9995% — not there yet — while the much larger market for merely 99% material is one they intend to attack anyway; ytterbium moves to continuous production next month, at which point it can ship.
Two structural events are pending. The QLE spin-out — where existing ASPI holders are handed shares in the nuclear-fuel business — cannot happen before 13 September for US capital-gains reasons, and the exchange ratio has already been decided but not published (it is not one-for-one). It is waiting on a contract with Fermi, the operator of a Texas plant, which itself is waiting on a couple more tenants signing up. Separately, some odd-looking recent purchases (two properties, some gold) are simply a device to keep the company classified as a trading company for tax purposes while a Hong Kong building business is sold — they will likely be resold once a Kazakh transaction with Cove Kaz Capital closes, which is stuck on the mundane problem of finding an auditor for the asset.
The author's own conclusion is not a price target but a temperament argument. Twenty-odd years ago he held a small UK software company, GB Group, through four years of delays and two profit warnings while the share price went 33p → 50p → 15p → 33p and other investors complained bitterly about management. He sold, made about £2,500 — and then watched it run to nearly 1000p, which on his 600,000 shares in a tax-free account would have been about £6m. He is explicit that he is not predicting the same outcome here, only that the tone of the complaints "does seem awfully familiar," and that everyone should do their own work.
Renergen is the operating business behind ASP Isotopes' helium story: a gas project at Virginia in South Africa's Free State that produces helium along with methane, which is chilled into LNG (liquefied natural gas) and sold to industrial and transport customers. It now sits inside ASP Isotopes rather than standing alone — its COO, Nick Mitchell, was on this call beside the ASPI CEO — so this entry is about the asset, and the way to own it is the parent.
Where it stands: the plant is in commissioning, which is the shakedown phase between "built" and "running properly," and management expects that finished with first shipments early next month. In parallel they are signing customers — targeting three-quarters of Stage 1 output contracted by the end of next month and half of Stage 2 by the end of the year. That order matters: the lenders behind the $750m package want to see contracted volume before they release money, so the sales book is deliberately being built ahead of the build-out.
The economics reported here are strong. Helium's first contract was done at $600 per mcf, with management saying it is now seeing "potentially up to $1,000" — and crucially on take-or-pay terms running five to fifteen years, so the buyer is committed to pay for the volume regardless of whether they take it. Helium has no exchange-traded spot price; every deal is negotiated privately, which is why hearing a realised contract number straight from a producer is genuinely informative. The LNG by-product sells for a comparatively ordinary $15 to $20.
PET Labs is ASP Isotopes' nuclear-medicine business in South Africa — it makes the short-lived radioactive tracers used in PET scans and, increasingly, the isotopes used to treat cancer directly. It is not separately listed; it sits inside ASPI, and it is the part of the group closest to producing real, recurring revenue today.
On this call management said PET Labs is "growing very rapidly" and expects to reach $150m of nuclear-medicine revenue by the end of the decade. The poster adds that he believes this figure includes the ytterbium-derived isotope stream, but flags that as his own reading rather than something confirmed on the call — so treat the $150m as the number and its composition as unverified.
Noble Africa is the entity ASP Isotopes intends to list on Nasdaq to hold the helium business. Its role in this call is financing plumbing: after the DFC and Standard Bank conditions are satisfied, another $250m of equity is needed, and management says that money will be raised at the Noble Africa level rather than at ASPI's — "any dilution should fall on it," with ASPI keeping 89% of the subsidiary afterwards.
"Dilution" simply means issuing new shares so existing holders own a smaller slice. Doing it at a subsidiary is a way to fund a project without shrinking the parent's shareholders' stake in everything else the parent owns — though the parent's share of the subsidiary still falls, which is exactly what the 89% figure describes. The member who attended flagged honest uncertainty here: "Not sure how that works with the dilution though they do have plenty of cash for that purpose." Until the listing documents exist this is a stated intention rather than a completed structure, which is why the stance is neutral — no view on price, only on the mechanism.
Quantum Leap Energy is ASP Isotopes' nuclear-fuel venture — the business aimed at supplying enriched fuel for advanced and small modular reactors. The plan is to spin it out: hand shares in QLE directly to existing ASPI shareholders so it trades as its own company, which is a common way to reveal value the market is not crediting inside a group.
The update here is entirely about timing and mechanics. The spin-out cannot happen before 13 September, the anniversary of the original stock-market listing, for US capital-gains-tax reasons — but "could happen quite quickly after this point." ASPI holders will receive QLE shares on a ratio that has already been decided but is not one-for-one and has not been disclosed, so nobody outside can yet work out what a share of ASPI is entitled to.
What actually releases it is commercial, not legal: a contract with Fermi, which operates a Texas plant, is described as "very close" and needs only a couple more tenants signed at that site. Once the Fermi deal is announced, the QLE arrangement is expected to be made public. That gives a clean, watchable sequence — tenants, then the Fermi contract, then the QLE announcement, then the spin-out — with no price or valuation attached to any of it, which is why this sits neutral.
Analysis of a member post in a private Discord community's #general channel, relaying that member's own notes from a Red Chip small-group investor call. Management gave no price or valuation view; the multiple-based valuation discussed was the call participants'. Not investment advice.